Pfizer's COVID-19 vaccine 94% effective for people above 65, no safety concerns reported

On vember 18, US pharmaceutical company Pfizer anunced that its mRNA-based COVID-19 vaccine has proven to be 94 percent effective in preventing SARS-CoV-2 infection in people over 65-years-old. “ serious safety concerns” were reported in 43,000 volunteers that were ministered with trial doses, firm informed, ding, that it has met safety criteria needed for emergency authorization. Furrmore, Pfizer and BioNTech said that y planned to submit efficacy report to US regulator for emergency use approval "within days." 

According to Pfizer’s first interim efficacy analysis report, at least 42 percent of participants enrolled were having diverse backgrounds, and despite that, serious safety concerns related to vaccine were observed. company said that it achieved safety milestone with reps t to its mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 with demonstrated efficacy evidence studied by  independent Data Monitoring Committee (DMC) from clinical trials.

“ study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at speed of science to compile all data collected thus far and share with regulators around world,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

“With hundreds of thousands of people around globe infected every day, we urgently need to get a safe and effective vaccine to world.”

Re:  Stor Of Pfizer's COVID Vaccine Challenge For Most Nations; India Examining Possibilities: Govt

Re: 'We Share Common Goal': Pfizer CEO 'thrilled' About Moderna's COVID-19 Vaccine Result

Overall 95 percent effective

In its primary efficacy analysis, Pfizer’s vaccine candidate BNT162b2  proved to be overall 95 percent effective just merely 28 days after first dose. At least 170 confirmed cases of COVID-19 were evaluated, with 162 observed in placebo group versus 8 in vaccine group, firm informed. Efficacy was consistent across , , race, and ethnicity demographics, it ded. Of total 43,000 participants enrolled, only 2 percent reported fatigue at 3.8 percent and heache at 2.0 percent as only Gre 3 verse event. M.D., CEO and Co-founder of BioNTech, Ugur Sahin said, “We are grateful that first global trial to reach final efficacy analysis mark indicates that a high rate of protection against COVID-19 can be achieved very fast after first 30 µg dose, underscoring power of BNT162 in providing early protection.”

Re: Pfizer: COVID-19 Shot Seems Effective In Elderly

Re: It's Moderna Vs Pfizer As US Covid Vaccines Score 90%+ Trials Success; Which Has Edge?

(im Credit: AP)